A tale of two inhibitors: diarylquinolines and squaramides
The EMBO Journal · 2023
DOI: 10.15252/embj.2023114912 ↗Kurz gefasst
Kommentar in der Zeitschrift The EMBO Journal, 2023. Verfasst von James Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, NYU School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Diarylquinolines, Mycobacterium tuberculosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
The diarylquinoline bedaquiline (BDQ) is an FDA‐approved drug for the treatment of multidrug‐resistant tuberculosis that targets the mycobacterial adenosine triphosphate (ATP) synthase, a key enzyme in cellular respiration. In a recent study, Courbon et al (2023) examine the interaction between Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ‐876 and the squaramide inhibitor SQ31f, showing that both drugs prevent the rotatory motions needed for enzymatic function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, NYU School of Medicine, New York, NY, USA.
- Department of Microbiology, NYU School of Medicine, New York, NY, USA.
ORCID-Profile: James Chen, Damian C Ekiert
Förderung
- NIAID NIH HHS
Zitieren
APA
Chen, J., & Ekiert, D. C. (2023). A tale of two inhibitors: diarylquinolines and squaramides. The EMBO Journal. https://doi.org/10.15252/embj.2023114912
Vancouver
Chen J, Ekiert DC. A tale of two inhibitors: diarylquinolines and squaramides. The EMBO Journal. 2023. doi:10.15252/embj.2023114912
BibTeX
@article{Chen2023,
author = {Chen, James and Ekiert, Damian C},
title = {A tale of two inhibitors: diarylquinolines and squaramides},
journal = {The EMBO Journal},
year = {2023},
doi = {10.15252/embj.2023114912}
}
EUVIMED